2,577 results match your criteria Journal of thrombosis and thrombolysis[Journal]


Restenosis is associated with prothrombotic plasma fibrin clot characteristics in endovascularly treated patients with critical limb ischemia.

J Thromb Thrombolysis 2019 Feb 14. Epub 2019 Feb 14.

Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.

Introduction: Hypolysible fibrin clots composed of tightly packed fibers characterize patients with peripheral artery disease (PAD) especially those with critical limb ischemia (CLI). Little is known about the impact of a prothrombotic clot phenotype on restenosis following endovascular revascularization in CLI. The goal of this study was to compare fibrin clot properties and their determinants in CLI patients with restenosis after endovascular treatment (ET) and those free of this complication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01826-9DOI Listing
February 2019

Clinical implications of different risk factor profiles in patients with mesenteric venous thrombosis and systemic venous thromboembolism: a population-based study.

J Thromb Thrombolysis 2019 Feb 12. Epub 2019 Feb 12.

Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden.

It is unknown whether the risk factor profile for mesenteric venous thrombosis (MVT) is different from systemic venous thromboembolism (VTE). The aim of the present population-based study was to compare acquired and inherited risk factors in MVT versus VTE. Identification of all MVT patients at Skåne University Hospital between 2000 and 2015 was performed in patient records and AuriculA (Swedish anticoagulation registry). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01816-xDOI Listing
February 2019

A clinical practice-based evaluation of the RIETE score in predicting occult cancer in patients with venous thromboembolism.

J Thromb Thrombolysis 2019 Feb 9. Epub 2019 Feb 9.

Department of Clinical Sciences, Danderyd Hospital, Division of Internal Medicine, Karolinska Institutet, Stockholm, Sweden.

The association between venous thromboembolism (VTE) and occult cancer is well established. However, the benefit of cancer screening in all VTE patients remains controversial. The Registro Informatizado Enfermedad TromboEmbólica (RIETE) score is a recently proposed risk score to identify VTE patients at high risk of occult cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01822-zDOI Listing
February 2019
1 Read

Guided de-escalation of DAPT in acute coronary syndrome patients undergoing percutaneous coronary intervention with BVS implantation: a post-hoc analysis from the randomized TROPICAL-ACS trial.

J Thromb Thrombolysis 2019 Feb 9. Epub 2019 Feb 9.

Department of Cardiology, LMU München, Munich, Germany.

To investigate the safety and efficacy of an early platelet function testing (PFT)-guided de-escalation of dual antiplatelet treatment (DAPT) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) with bioresorbable vascular scaffolds (BVS). Early DAPT de-escalation is a new non-inferior alternative to 12-months DAPT in patients with biomarker positive ACS treated with stent implantation. In this post-hoc analysis of the TROPICAL-ACS trial, which randomized 2610 ACS patients to a PFT-guided DAPT de-escalation (switch from prasugrel to clopidogrel) or to control group (uniform prasugrel), we compared clinical outcomes of patients (n = 151) who received a BVS during the index PCI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01811-2DOI Listing
February 2019
1 Read

Impact of time in therapeutic range after left ventricular assist device placement: a comparison between thrombus and thrombus-free periods.

J Thromb Thrombolysis 2019 Feb 9. Epub 2019 Feb 9.

Advanced Heart Failure, Sentara Norfolk General Hospital, Norfolk, VA, USA.

The association between time in therapeutic range (TTR) and clinical outcomes in patients with left ventricular assist devices (LVADs) on chronic warfarin therapy is not well understood. This study assessed TTR using the Rosendaal Method prior to suspected or confirmed pump thrombosis or ischemic stroke. Each patient served as their own control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-01800-xDOI Listing
February 2019

Impaired endogenous fibrinolysis at high shear using a point-of-care test in STEMI is associated with alterations in clot architecture.

J Thromb Thrombolysis 2019 Feb 9. Epub 2019 Feb 9.

Postgraduate Medical School, University of Hertfordshire, Hertfordshire, UK.

Impaired endogenous fibrinolysis is an adverse prognostic biomarker in acute coronary syndrome (ACS). Abnormally dense in vitro fibrin thrombi have been demonstrated in ACS patients and related to hypofibrinolysis using cumbersome, laboratory-based methods. We aimed to assess endogenous fibrinolysis using a point-of-care technique and relate this to clot architecture. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-01799-1DOI Listing
February 2019

The value of sPESI for risk stratification in patients with pulmonary embolism.

J Thromb Thrombolysis 2019 Feb 7. Epub 2019 Feb 7.

Janssen Scientific Affairs, LLC, Titusville, NJ, USA.

Introduction: Various risk stratification methods exist for patients with pulmonary embolism (PE). We used the simplified Pulmonary Embolism Severity Index (sPESI) as a risk-stratification method to understand the Veterans Health Administration (VHA) PE population.

Materials And Methods: Adult patients with ≥ 1 inpatient PE diagnosis (index date = discharge date) from October 2011-June 2015 as well as continuous enrollment for ≥ 12 months pre- and 3 months post-index date were included. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11239-019-01814-z
Publisher Site
http://dx.doi.org/10.1007/s11239-019-01814-zDOI Listing
February 2019
2 Reads
2.039 Impact Factor

Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon.

J Thromb Thrombolysis 2019 Feb 7. Epub 2019 Feb 7.

Department of Otolaryngology, Head/Neck & Facial Plastic Surgery, Sana Kliniken Leipziger Land, Rudolf-Virchow-Strasse 2, 04552, Borna, Germany.

Patients taking oral anticoagulants (OACs) currently represent one-third of all patients treated for epistaxis and an upward trend is expected. New direct oral anticoagulants (DOACs) have been on the market for approximately 10 years. DOACs are favoured over Vitamin K-Antagonists (VKAs) in the current guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01824-xDOI Listing
February 2019

Thrombin generation profile in non-thrombotic factor V Leiden carriers.

J Thromb Thrombolysis 2019 Jan 30. Epub 2019 Jan 30.

Normandie Univ, UNIROUEN, INSERM U1096, Rouen University Hospital, Vascular Hemostasis Unit, F 76000, Rouen, France.

Factor V Leiden (FVL) mutation is the most common genetic risk factor for venous thromboembolism. In families with a history of thrombosis, FVL can be present in 18%. Thrombin generation test is commonly used as an evaluation tool of thrombotic risk. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11239-019-01821-0
Publisher Site
http://dx.doi.org/10.1007/s11239-019-01821-0DOI Listing
January 2019
4 Reads

Highlights from the 2018 European Society of Cardiology Congress in Munich, Germany.

Authors:
Dylan L Steen

J Thromb Thrombolysis 2019 Jan 30. Epub 2019 Jan 30.

University of Cincinnati, Cincinnati, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01810-3DOI Listing
January 2019

Body mass index reduction improves the baseline procoagulant imbalance of obese subjects.

J Thromb Thrombolysis 2019 Jan 30. Epub 2019 Jan 30.

IRCCS Cà Granda Maggiore Hospital Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi villa, Via Pace 9, 20122, Milano, Italy.

Obesity is a risk factor for cardiovascular diseases. The latter being dependent (at least in part) on plasma procoagulant imbalance (i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01818-9DOI Listing
January 2019

Thrombotic events in severe FXII deficiency in comparison with unaffected family members during a long observation period.

J Thromb Thrombolysis 2019 Jan 29. Epub 2019 Jan 29.

Department of Medicine, University of Padua Medical School, Via Ospedale, 105, 35128, Padua, Italy.

To investigate the occurrence of thrombotic events (myocardial infarction, deep vein thrombosis or ischemic stroke) in a group of 39 cases of severe FXII deficiency during a mean 22.5 years follow-up. All patients seen in Padua during the years 1968-2006 will the object of this investigation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01819-8DOI Listing
January 2019
1 Read

The comparative analysis of non-thrombotic internal jugular vein stenosis and cerebral venous sinus stenosis.

J Thromb Thrombolysis 2019 Jan 28. Epub 2019 Jan 28.

Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.

Internal jugular vein (IJV) stenosis and cerebral venous sinus (CVS) stenosis belong to cerebral venous outflow insufficiency. This study aimed to analyze the similarities and differences between IJV stenosis and CVS stenosis. Patients with either IJV stenosis or CVS stenosis confirmed by contrast-enhanced magnetic resonance venography between October 2017 and July 2018 were enrolled in this retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01820-1DOI Listing
January 2019

Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients.

J Thromb Thrombolysis 2019 Jan 28. Epub 2019 Jan 28.

Hematology Department, Hadassah-Hebrew University Medical Center, POB 12000, 91120, Jerusalem, Israel.

Direct oral anticoagulants (DOACs) are commonly administered at a level that is lower than that recommended by dose reduction criteria. This raises concern regarding the adequacy of anticoagulation achieved. To evaluate the relationship between inappropriate dosing and DOAC levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01815-yDOI Listing
January 2019

Unfavourably altered plasma clot properties in patients with primary Raynaud's phenomenon: association with venous thromboembolism.

J Thromb Thrombolysis 2019 Jan 25. Epub 2019 Jan 25.

John Paul II Hospital, Krakow, Poland.

Associations of Raynaud's phenomenon (RP) with venous thromboembolism (VTE) are unclear. We investigated the occurrence of RP together with prothrombotic state markers and fibrin clot properties in VTE patients. In this prospective cohort study we enrolled 360 patients free of known autoimmune disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01805-0DOI Listing
January 2019
1 Read

The efficacy and safety of a catheter removal only strategy for the treatment of PICC line thrombosis versus standard of care anticoagulation: a retrospective review.

J Thromb Thrombolysis 2019 Jan 23. Epub 2019 Jan 23.

Department of Hematology & Oncology, Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239, USA.

Peripherally-inserted central catheters (PICCs) are commonly used during hospitalization. Unfortunately, their use can be complicated by catheter-related thrombosis (CRT). Current guidelines recommend 3-6 months of anticoagulation for patients with CRT after catheter removal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01807-yDOI Listing
January 2019

"Blueprinting" thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke.

J Thromb Thrombolysis 2019 Jan 23. Epub 2019 Jan 23.

Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, 3300 Gallows Road, Falls Church, VA, USA.

Early assessment of thrombogenicity and antithrombotic drug effects may be important for therapeutic decision making in patients presenting with acute stroke. In this prospective, single center, pilot study, a bedside thrombelastography assay (TEG6s) was used to measure thrombogenicity and antithrombotic drug response in serial patients presenting emergently with symptoms of acute stroke (n = 90). TEG6s measures were compared against diagnosis obtained by NIH Stroke Scale/Score and imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01813-0DOI Listing
January 2019

Influence of baseline anemia on long-term clinical outcomes in patients with venous thromboembolism: from the COMMAND VTE registry.

J Thromb Thrombolysis 2019 Jan 23. Epub 2019 Jan 23.

Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

The influence of anemia on the long-term clinical outcomes has not been fully evaluated in patients with venous thromboembolism (VTE). We evaluated the influence of anemia among 3012 patients in the COMMAND VTE Registry with a median follow-up period of 1219 days. The outcomes measures were ISTH major bleeding, recurrent VTE and all-cause death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1791-2DOI Listing
January 2019
1 Read

Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis.

J Thromb Thrombolysis 2019 Jan 23. Epub 2019 Jan 23.

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.

Anti-platelet agents or anticoagulants are administered for patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs) to prevent thrombotic events (TEs). However, there is a discrepancy between current guidelines and clinical practice in thromboprophylaxis and the varied incidence of TEs depending on patient cohort. Therefore, a consensus on the optimal thromboprophylactic strategy is needed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01809-wDOI Listing
January 2019

The impact of smoking on mortality after acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: a retrospective cohort outcome study at 3 years.

J Thromb Thrombolysis 2019 Jan 21. Epub 2019 Jan 21.

The South Yorkshire Cardiothoracic Centre, Northern General Hospital, Sheffield, UK.

The "smoker's paradox", where smokers have improved survival post-myocardial infarction, was predominantly observed in the thrombolytic era. However, evidence for the smoker's paradox in the current era of PCI therapy is both limited and inconsistent. We aimed to examine the effect of smoking status on survival in unselected ST-elevation myocardial infarction (STEMI) patients managed by primary percutaneous coronary intervention (PCI). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11239-019-01812-1
Publisher Site
http://dx.doi.org/10.1007/s11239-019-01812-1DOI Listing
January 2019
4 Reads

Thromboembolism in children with cancer: a retrospective multicenter study in Korea.

J Thromb Thrombolysis 2019 Jan 21. Epub 2019 Jan 21.

Department of Pediatrics, Seoul National University Hospital, 101, Daehak-ro, Jongno-gu, 03080, Seoul, Republic of Korea.

Thromboembolism (TE) is a major cause of morbidity and mortality in adult cancer patients; however, there is a lack of sufficient knowledge on TE in pediatric cancer patients. We aimed to determine the epidemiology of TE in Korean children with cancer. Between January 2000 and July 2015, we retrospectively analyzed pediatric patients newly diagnosed with cancer at six tertiary hospitals in Korea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01808-xDOI Listing
January 2019
1 Read

Patterns in anticoagulant utilization in the Czech Republic during 2007-2017.

J Thromb Thrombolysis 2019 Jan 18. Epub 2019 Jan 18.

Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic.

Direct oral anticoagulants (DOACs) have gradually entered the Czech market as alternatives to vitamin K antagonists and parenteral anticoagulants since 2008. Considering the eventual changes, the aim was to evaluate drug use and expenditure patterns on anticoagulants in the Czech Republic. A retrospective utilization study was conducted retrieving data from the State Institute for Drug Control database, including reports on drug supplies from distributors with anatomical therapeutic chemical classification (ATC) codes B01AA, B01AB, B01AE, B01AF, and B01AX. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-019-01806-zDOI Listing
January 2019
1 Read

The relationship between the prognosis of children with acute arterial stroke and polymorphisms of CDKN2B, HDAC9, NINJ2, NAA25 genes.

J Thromb Thrombolysis 2019 Jan 17. Epub 2019 Jan 17.

Betul-Ziya Eren Genome and Stem Cell Center (GENKOK), Erciyes University Medical Faculty, Kayseri, Turkey.

Ischemic stroke is a significant health condition, whose frequency in childhood is increasing day by day. Although many factors are effective in development of the stroke, it has been showed that individuals having risk factors have a genetic predisposition. The aim of the study is to determine whether distinct genetic mutations are risk factors for children with history of ischemic stroke. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11239-018-01802-9
Publisher Site
http://dx.doi.org/10.1007/s11239-018-01802-9DOI Listing
January 2019
6 Reads

Association study of miR-146a, miR-149, miR-196a2, and miR-499 polymorphisms with venous thromboembolism in a Korean population.

J Thromb Thrombolysis 2019 Jan 12. Epub 2019 Jan 12.

Department of Biomedical Science, College of Life Science, CHA University, 335 Pangyo-ro, Bundang-gu, Seongnam, South Korea.

Despite much progress in microRNA (miRNA) research, information regarding the association between miRNAs and venous thromboembolism (VTE), especially in Asian patients, remains limited. This case-control study sought to determine the correlation between the presence of polymorphisms in the genes encoding the miRNAs miR-146a, miR-149, miR-196a2, miR-499, and VTE in Korean patients. We observed no statistically significant differences in the genotype frequency of miRNA polymorphisms between 300 control individuals and 203 VTE patients. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11239-018-1778-z
Publisher Site
http://dx.doi.org/10.1007/s11239-018-1778-zDOI Listing
January 2019
4 Reads

Individual differences of plasma proteins and factors in fresh frozen plasma from Chinese regional blood donors.

J Thromb Thrombolysis 2019 Jan 12. Epub 2019 Jan 12.

Department of Blood Transfusion, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, China.

Currently, single fresh frozen plasma (FFP) for clinical use is derived from individual blood donors. The objective of this study is to investigate the differences in single FFP units to make related strategies for improving FFP transfusion efficacy. 120 units of single FFP were selected randomly from Chinese PLA Clinical Blood Transfusion Center in Beijing, China. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1789-9DOI Listing
January 2019
3 Reads

Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers.

J Thromb Thrombolysis 2019 Jan 8. Epub 2019 Jan 8.

Department of Medicine, Hadassah Hebrew University Medical Center, Mt Scopus, 91540, Jerusalem, Israel.

Little is known regarding the management of direct oral anticoagulants (DOACs) in patients with enzyme-inducing drugs (EID). The use of EID may lead to sub-therapeutic concentrations of DOACs and to treatment failure. Thus, many patients on EIDs cannot benefit from the advantages of DOACs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-01804-7DOI Listing
January 2019
1 Read

Awareness and management of pulmonary embolism among physicians in China: a nationwide cross-sectional study.

J Thromb Thrombolysis 2019 Jan 5. Epub 2019 Jan 5.

Department of Respiratory Disease, Capital Medical University, 2 Yinghua Dongjie, Hepingli, Chaoyang District, Beijing, 100029, China.

Pulmonary embolism (PE) is a leading cause of cardiovascular mortality. We intended to evaluate the awareness and management status of PE among Chinese physicians and provide the basis for establishing Chinese clinical guidelines on PE. We designed a nationwide survey to collect data on physicians' awareness of diagnosis, treatment and follow-up on PE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1788-xDOI Listing
January 2019
1 Read

Limited impact of clinician education on reducing inappropriate PF4 testing for heparin-induced thrombocytopenia.

J Thromb Thrombolysis 2019 Jan 5. Epub 2019 Jan 5.

Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, 39 Sabin St, MSC 635, Charleston, SC, 29425, USA.

A high frequency of PF4-ELISA testing in patients suspected to have heparin-induced thrombocytopenia (HIT) despite low 4T scores has been observed in multiple medical centers. Education of clinicians has been suggested to reduce inappropriate testing. We determined trends of PF4-ELISA testing in our institution after the introduction of a HIT education program for clinicians. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-01803-8DOI Listing
January 2019

PADUA score as a predictor for pulmonary embolism: a potential strategy for reducing unnecessary imaging.

J Thromb Thrombolysis 2019 Jan 5. Epub 2019 Jan 5.

Department of Surgery, Henry Ford Health System, Wayne State University, Detroit, MI, USA.

An objective tool that is easy to integrate with an electronic medical record may help reduce unnecessary imaging for diagnosing a pulmonary embolism (PE). In this study, we assess the PADUA score in stratifying patients based on their risk of a PE. We reviewed charts of patients that underwent a computed tomography pulmonary angiogram (CT-PA) between January 2014 and September 2015 at our institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-01801-wDOI Listing
January 2019

The reduced form of coagulation factor XI is associated with illness severity and coagulopathy in critically-ill septic patients.

J Thromb Thrombolysis 2019 Jan 2. Epub 2019 Jan 2.

Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.

Coagulation Factor XI (FXI) contributes to the pathobiology of sepsis-associated thrombosis and is a target for new therapeutics. Through cleavage of disulfide bonds, FXI becomes reduced (rFXI), accelerating intrinsic coagulation cascade activation. The role of rFXI in human sepsis has never been studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1797-9DOI Listing
January 2019
4 Reads

Assessment of direct oral anticoagulant assay use in clinical practice.

J Thromb Thrombolysis 2019 Jan 2. Epub 2019 Jan 2.

Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.

There are no clear and consistent guidelines on how to utilize DOAC assays, and reports on the use of DOAC levels in clinical practice is limited. The objective of this study was to analyze why DOAC levels are ordered, how the results affect clinical decision-making, and to determine if DOAC assays are utilized appropriately. This was a retrospective chart review study analyzing 150 dabigatran, rivaroxaban, and apixaban levels performed at a single institution. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11239-018-1793-0
Publisher Site
http://dx.doi.org/10.1007/s11239-018-1793-0DOI Listing
January 2019
4 Reads

Deep vein thrombosis in a well-trained masters cyclist, is popliteal vein entrapment syndrome to blame?

J Thromb Thrombolysis 2018 Dec 19. Epub 2018 Dec 19.

Sport Performance Optimisation Research Team, School of Health Sciences, University of Tasmania, Tasmania, Australia.

Whilst athletes are the epitome of health, venous thromboembolisms (VTE) including deep vein thrombosis and pulmonary embolism have been demonstrated to occur in well-trained athletes. VTE is frequently misdiagnosed and poorly treated within this population, often resulting in career or life-threatening ramifications. Furthermore, VTE risk rises with increasing age (> 40 years), potentially affecting masters athletes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1796-xDOI Listing
December 2018

Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia.

J Thromb Thrombolysis 2018 Dec 18. Epub 2018 Dec 18.

Cardiovascular Division, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.

Patients with thrombocytopenia were excluded from major clinical trials that investigated non-vitamin-K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation (AF). The aim of this study was to evaluate the effectiveness and safety of NOAC versus warfarin in AF patients with thrombocytopenia. From 2010 to 2017, a cohort study based on electronic medical records of a multi-center healthcare provider in Taiwan and included 8239 anticoagulated AF patients (age 77. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1792-1DOI Listing
December 2018

Characteristics of patients presenting with myocardial infarction with non-obstructive coronary arteries (MINOCA) in Poland: data from the ORPKI national registry.

J Thromb Thrombolysis 2018 Dec 18. Epub 2018 Dec 18.

Institute of Cardiology, Jagiellonian University Medical College, Kopernika 17 Street, 31-501, Kraków, Poland.

Myocardial infarction (MI) with non-obstructive coronary arteries (MINOCA) is an important clinical problem especially in the era of extensive utilization of coronary angiography in MI patients. Its pathophysiology is poorly understood which makes diagnostics and treatment of MINOCA challenging in everyday clinical practice. The aim of the study was to assess characteristics of MINOCA patients in Poland based on data from the Polish National ORPKI Registry. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11239-018-1794-z
Publisher Site
http://dx.doi.org/10.1007/s11239-018-1794-zDOI Listing
December 2018
5 Reads

Venous thromboembolism in patients with cancer undergoing surgical exploration.

J Thromb Thrombolysis 2018 Dec 17. Epub 2018 Dec 17.

Division of Surgical Oncology, Northwell Health, 450 Lakeville Rd, Lake Success, NY, 11042, USA.

Malignancy and surgery are both independent risk factors for venous thromboembolism (VTE) events. The current NCCN guidelines recommend VTE prophylaxis for up to 28 days after major abdominal or pelvic surgery for malignancy. We set out to evaluate the rate and timing of VTEs among patients with gastric, pancreatic, colorectal, and gynecologic malignancies who underwent surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1774-3DOI Listing
December 2018
2 Reads
2.039 Impact Factor

Thromboembolism and bleeding in patients with cancer and mechanical heart valves.

J Thromb Thrombolysis 2018 Dec 17. Epub 2018 Dec 17.

Department of Hematology, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona, Ctra. Canyet s/n, 08916, Badalona, Spain.

Mechanical heart valves (MHV) require life-long anticoagulation with vitamin K antagonists (VKA), but anticoagulation management is complex in patients with cancer due to a high risk of thrombosis and bleeding. This is a retrospective, single-center study to assess anticoagulation management and thrombotic (stroke/valve thrombosis) and bleeding events in patients with active cancer and MHV. The incidence of thrombotic complications was compared to a control group (matched 1:1) of patients with MHV but without cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1790-3DOI Listing
December 2018
1 Read

Resource utilization and hospital readmission associated with gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices.

J Thromb Thrombolysis 2018 Dec 6. Epub 2018 Dec 6.

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Gastrointestinal bleeding (GIB) occurs in up to 40% of patients with continuous-flow (CF) left ventricular assist devices (LVADs). We sought to identify targets to improve hospital resource utilization and decrease readmissions after GIB. We performed a single-center, retrospective analysis of LVAD-associated GIB resulting in hospital admission between July 2011 and April 2014. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11239-018-1781-4
Publisher Site
http://dx.doi.org/10.1007/s11239-018-1781-4DOI Listing
December 2018
4 Reads

Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients.

J Thromb Thrombolysis 2018 Nov 30. Epub 2018 Nov 30.

Division of Hematology/Oncology, St. Michael's Hospital, Toronto, ON, Canada.

Direct oral anticoagulants (DOACs) have become the standard for thromboembolic risk management. In cases of major bleeding, trauma, or urgent surgery, accurate monitoring of DOAC activity is desirable; however, there is often no rapid, readily available test. We therefore explored the degree to which DOAC activity correlated with two coagulation assays: rotational thromboelastometry (ROTEM) and a standard coagulation assay in bleeding patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1785-0DOI Listing
November 2018
1 Read

Correction to: Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysis.

J Thromb Thrombolysis 2019 Jan;47(1):41

Center for Vascular Emergencies, Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

The original version of the article unfortunately contained an error in conflict of interest. This erratum is published with the correct conflict of interest. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11239-018-1787-y
Publisher Site
http://dx.doi.org/10.1007/s11239-018-1787-yDOI Listing
January 2019
7 Reads

Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials.

J Thromb Thrombolysis 2018 Dec 3. Epub 2018 Dec 3.

Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.

Recurrent stroke is common immediately following a transient ischemic attack (TIA) or ischemic stroke. Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin may provide greater protection against subsequent stroke than monotherapy. Electronic databases were searched for randomized clinical trials (RCTs) comparing DAPT with monotherapy in ischemic stroke/TIA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1786-zDOI Listing
December 2018
2 Reads

Restrictive versus liberal red blood cell transfusion for cardiac surgery: a systematic review and meta-analysis of randomized controlled trials.

J Thromb Thrombolysis 2018 Dec 3. Epub 2018 Dec 3.

Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.

Patients undergoing cardiac surgery are among the most common recipients of allogeneic red blood cell (RBC) transfusions. However, whether restrictive RBC transfusion strategies for cardiac surgery achieve a similar clinical outcome in comparison with liberal strategies remains unclear. We searched electronic databases from inception to December 2017 for randomized controlled trials (RCTs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1784-1DOI Listing
December 2018
2 Reads

Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function.

J Thromb Thrombolysis 2018 Dec 3. Epub 2018 Dec 3.

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Rd., Suite 7022, Boston, MA, 02115, USA.

Patients with renal disease are often undertreated with antiplatelet therapy due to concerns about bleeding. Vorapaxar blocks platelet activation via the PAR-1 receptor and reduces cardiovascular events in patients with stable atherosclerosis, but with increased bleeding. We examined the efficacy and safety of vorapaxar in patients with impaired renal function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1779-yDOI Listing
December 2018

Elevated lipoprotein(a) as a new risk factor of cerebral venous sinus thrombosis: association with fibrin clot properties.

J Thromb Thrombolysis 2019 Jan;47(1):8-15

Institute of Cardiology, Jagiellonian University Medical College, 80 Pradnicka St, 31-202, Cracow, Poland.

Elevated lipoprotein(a) [Lp(a)] has been reported to be associated with prothrombotic clot phenotype. We hypothesized that increased Lp(a) contributes to cerebral venous sinus thrombosis (CVST) and its recurrence in relation to clot features. In 80 consecutive patients (aged 39. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1769-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336752PMC
January 2019
2 Reads

Changes in thromboinflammatory profiles across the generations of transcatheter aortic heart valves.

J Thromb Thrombolysis 2018 Nov 27. Epub 2018 Nov 27.

Gill Heart and Vascular Institute, University of Kentucky, BBSRB B345, Lexington, KY, 40506, USA.

The transcatheter aortic valve replacement (TAVR) procedure was developed to provide patients with severe aortic stenosis an alternative to the surgical aortic valve replacement. Since the approval of the original SAPIEN the technology has rapidly evolved. While several approaches can be used for valve deployment, as delivery systems have become smaller and more flexible, the transfemoral approach has become the dominant technique for valve deployment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1782-3DOI Listing
November 2018

Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.

J Thromb Thrombolysis 2019 Jan;47(1):155-156

Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco Hospital, University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1773-4DOI Listing
January 2019
1 Read

Correction to: Direct oral anticoagulants for the treatment of venous thromboembolism in patients with active malignancy: a systematic review and meta-analysis.

J Thromb Thrombolysis 2019 Jan;47(1):166

Center for Health Outcomes and Pharmacoeconomic Research, Department of Pharmacy Practice and Science, College of Pharmacy, Department of Family and Community Health, College of Medicine, University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.

Unfortunately the author list in the original article is incomplete. The correct list of contributing authors is given in this Correction. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11239-018-1777-0
Publisher Site
http://dx.doi.org/10.1007/s11239-018-1777-0DOI Listing
January 2019
7 Reads

Direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: focus on real life studies.

J Thromb Thrombolysis 2018 Nov 23. Epub 2018 Nov 23.

Internal Medicine, Stroke Unit and Center of Thromboembolic Diseases, Santa Maria Nuova Hospital, Florence, Italy.

Strong evidence for the use of direct oral anticoagulants (DOACs) in the early phase of non valvular atrial fibrillation (NVAF)-related acute ischemic stroke (AIS) is lacking, because this kind of patients were excluded from phase III randomized clinical trials (RCT) and ad hoc RCTs are ongoing. In the latest years a lot of real life studies on this topic have been published. The aim of our review was to focus on these. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11239-018-1775-2
Publisher Site
http://dx.doi.org/10.1007/s11239-018-1775-2DOI Listing
November 2018
8 Reads

Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.

J Thromb Thrombolysis 2018 Nov 22. Epub 2018 Nov 22.

Department of Internal Medicine, Torrejón University Hospital, Mateo Inurria, s/n (Soto del Henares), 28850, Torrejón de Ardoz, Madrid, Spain.

Cancer is associated with an increased risk of venous thromboembolism of four to sixfold. Cancer-related interventions such as chemotherapy, hormonal therapy and indwelling central venous catheters also increase the risk of venous thromboembolism. Low molecular weight heparin for at least 3-6 months is the current standard of care for the treatment of cancer associated venous thromboembolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1783-2DOI Listing
November 2018
7 Reads

Combination index of the concentration and in vivo antagonism activity of racemic warfarin and its metabolites to assess individual drug responses.

J Thromb Thrombolysis 2018 Nov 21. Epub 2018 Nov 21.

Unit of Medical Pharmacy, Department of Pharmacy Practice, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto-machi, Nagasaki, 852-8588, Japan.

The present study was undertaken to examine whether in vivo vitamin K epoxide reductase complex 1 (VKOR) "actual" antagonism activity, calculated by the concentrations and the reported anticoagulant activities of the R- and S-warfarin enantiomers and their metabolites, correlates with the weekly dose of warfarin. Five patients under palliative care were enrolled in our study and 20 serum samples were analyzed by an enantioselective high-performance liquid chromatography-ultraviolet detection method. In vivo VKOR inhibition activities of S-warfarin, R-warfarin, 7- and 10-hydroxywarfarin were calculated as the ratio of drug or metabolite concentration to the IC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11239-018-1780-5DOI Listing
November 2018